Addressing Antimicrobial Resistance
Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics, making infections harder to treat and increasing the risk and spread of disease. AMR is an urgent health challenge—leading to more than 1.27M deaths globally each year. And its toll is only expected to grow; by 2050, it is estimated there will be 10M deaths from AMR each year.
Teva, one of the world’s largest manufacturer of antibiotics, works to address AMR by:
Collaborating to identify solutions. We serve on the board of the AMR Industry Alliance (AMRIA), which convenes more than 100 healthcare companies and associations. We also contribute to the AMR Action Fund, the world’s largest public-private partnership investing in new antimicrobial initiatives.
Promoting access to medicines. We develop a broad portfolio of antibiotics and anti-infectives, including 46% of those on the WHO's Essential Medicines List (EML). We get these treatments to more patients through donations and global health tenders.
Reducing the environmental impact of antibiotics. We actively seek to minimize the discharge of antimicrobial compounds from our own manufacturing and extended supply chain. We are one of the first companies to participate in BSI’s certification program, which provides third-party verification that an antibiotic has been manufactured according to AMRIA’s Manufacturing Discharge Standard, minimizing the risk of releasing harmful residuals into the environment. We also helped develop AMRIA’s Antibiotic Discharge Targets for environmental risk assessments, as well as its Global AMR Certification to promote responsible manufacturing of antibiotics.
Increasing awareness and encouraging appropriate antibiotic use. We create educational materials and tools to educate patients and healthcare providers about AMR.